Equities Analysts Offer Predictions for GLUE Q4 Earnings

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) - Analysts at Wedbush issued their Q4 2026 earnings per share estimates for shares of Monte Rosa Therapeutics in a research note issued on Thursday, May 8th. Wedbush analyst R. Driscoll anticipates that the company will earn ($0.57) per share for the quarter. Wedbush currently has a "Outperform" rating and a $17.00 target price on the stock. The consensus estimate for Monte Rosa Therapeutics' current full-year earnings is ($1.49) per share.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.57 earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.81. The company had revenue of $84.93 million for the quarter, compared to the consensus estimate of $13.57 million.

GLUE has been the subject of a number of other research reports. Lifesci Capital assumed coverage on Monte Rosa Therapeutics in a research report on Wednesday, March 12th. They set an "outperform" rating and a $19.00 price objective for the company. Wells Fargo & Company reduced their price objective on Monte Rosa Therapeutics from $11.00 to $10.00 and set an "equal weight" rating for the company in a research report on Friday, March 21st.

Monte Rosa Therapeutics Price Performance

GLUE stock traded up $0.11 on Monday, reaching $3.98. 421,565 shares of the company traded hands, compared to its average volume of 1,060,468. Monte Rosa Therapeutics has a one year low of $3.21 and a one year high of $12.40. The company has a market cap of $244.81 million, a P/E ratio of -2.17 and a beta of 1.52. The firm has a fifty day simple moving average of $4.83 and a 200-day simple moving average of $6.40.

Insider Buying and Selling at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, Director Chandra P. Leo bought 10,000 shares of Monte Rosa Therapeutics stock in a transaction on Monday, March 24th. The stock was acquired at an average price of $5.84 per share, with a total value of $58,400.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at approximately $58,400. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 6.90% of the company's stock.

Institutional Trading of Monte Rosa Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. increased its holdings in shares of Monte Rosa Therapeutics by 122.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company's stock worth $1,652,000 after purchasing an additional 196,238 shares in the last quarter. Parkwood LLC increased its holdings in shares of Monte Rosa Therapeutics by 119.2% in the 1st quarter. Parkwood LLC now owns 708,000 shares of the company's stock worth $3,285,000 after purchasing an additional 385,000 shares in the last quarter. BVF Inc. IL increased its holdings in shares of Monte Rosa Therapeutics by 104.7% in the 1st quarter. BVF Inc. IL now owns 5,660,132 shares of the company's stock worth $26,263,000 after purchasing an additional 2,895,661 shares in the last quarter. AQR Capital Management LLC bought a new stake in shares of Monte Rosa Therapeutics in the 1st quarter worth $1,065,000. Finally, Trexquant Investment LP bought a new stake in shares of Monte Rosa Therapeutics in the 1st quarter worth $122,000. Institutional investors own 79.96% of the company's stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.